Novo Nordisk Signs Agreements for Almost €1 Billion with Laboratories Supported by Flagship

Novo Nordisk signs new agreements. The Danish pharmaceutical company, owner of the weight loss treatment Wegovy, has announced independent research collaboration agreements with Omega Therapeutics and Cellarity, within the framework of the cooperation between Flagship Pioneering and the Scandinavian company, by which each of the laboratories biotechnological companies could receive up to $532 million (€486 million).

These agreements are made with the aim of developing novel therapeutic approaches for cardiometabolic diseases. In this sense, Omega will take advantage of the technological collaboration of its patented platform to develop an epigenomic controller designed to improve metabolic activity as part of a possible new approach in the treatment for the control of obesity, in a context in which many therapeutic interventions Exists for weight control have focused on appetite regulation.

For its part, Cellarity’s collaboration aims to discover new biological drivers of Mash , one of the main causes of chronic liver disease that carries a higher risk of developing type 2 diabetes and cardiovascular diseases . The pharmaceutical company will take advantage of its platform to develop a small molecule therapy against this disease.

Read more about the latest agreements closed by Novo Nordisk and find the most important financial news of the day with the Born2Invest mobile app.

Novo Nordisk increases its production of drugs against obesity and diabetes

Marcus Shindler, executive vice president and chief scientist at Novo Nordisk, said: “This is an important moment in our partnership with Flagship Pioneering; We look forward to advancing these research programs with Omega and Cellarity in the coming years as we explore bold new treatment strategies with the potential to have a significant impact for people living with obesity or Mash,” says Schindler.

Last November 2023, Novo Nordisk announced that it would invest more than 42 million Danish crowns (€5.63 billion) in expanding its facilities in Kalundborg (Denmark) to meet the high demands for its anti-obesity treatments, Wegovy, and against diabetes, Ozempic.

Thanks to the increases in Wegovy sales, Novo Nordisk recorded a net profit of 61.72 billion Danish crowns (€8.27 billion) in the first nine months of 2023 , which materialized in an increase of 47% compared to the same period in 2022. Regarding the figure for its solution against obesity, the value multiplied by six until the third quarter of the year, totaling 21.73 billion Danish crowns (€2.9 billion).

__

(Featured image by Joa70 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.